Co-Authors
This is a "connection" page, showing publications co-authored by RONALD A DEPINHO and ANDREA VIALE.
Connection Strength
1.044
-
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer. Cell. 2019 Nov 14; 179(5):1239.
Score: 0.184
-
Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature. 2017 02 02; 542(7639):119-123.
Score: 0.151
-
Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome. Cancer Cell. 2015 May 11; 27(5):644-57.
Score: 0.135
-
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014 Oct 30; 514(7524):628-32.
Score: 0.128
-
Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014 Jul 03; 158(1):185-197.
Score: 0.126
-
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012 Apr 27; 149(3):656-70.
Score: 0.109
-
KRAS inhibition activates an actionable CD24 'don't eat me' signal in pancreas cancer. bioRxiv. 2023 Sep 23.
Score: 0.060
-
Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature. 2019 04; 568(7752):410-414.
Score: 0.044
-
Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature. 2017 02 16; 542(7641):362-366.
Score: 0.038
-
In?Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Rep. 2016 06 28; 16(1):133-147.
Score: 0.036
-
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer. Cancer Res. 2015 Mar 15; 75(6):1091-101.
Score: 0.033